Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiagabine.

S C Schachter1

  • 1Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.

Epilepsia
|October 26, 1999
PubMed
Summary
This summary is machine-generated.

Tiagabine (TGB), a novel antiepileptic drug, effectively treats partial seizures by uniquely inhibiting GABA reuptake. It offers predictable pharmacokinetics and manageable side effects, making it a valuable option for refractory epilepsy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition.

Epilepsy research·2015
Same author

Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.

Neuroscience·2007
Same author

Oxcarbazepine: current status and clinical applications.

Expert opinion on investigational drugs·2005
Same author

Vagus nerve stimulation: current status and clinical applications.

Expert opinion on investigational drugs·2005
Same author

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Neurology·2004
Same author

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Neurology·2004
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Tiagabine (TGB) is a new antiepileptic drug (AED).
  • It uniquely inhibits gamma-aminobutyric acid (GABA) reuptake.
  • This mechanism is distinct among current AEDs.

Purpose of the Study:

  • To evaluate the efficacy and safety of Tiagabine (TGB) as adjunctive therapy for partial seizures.
  • To assess TGB's pharmacokinetic profile and drug interactions.
  • To explore the potential for TGB monotherapy in medically refractory epilepsy.

Main Methods:

  • Controlled clinical studies were conducted.
  • Pharmacokinetic parameters and drug interactions were analyzed.
  • Efficacy and adverse events were systematically recorded.

Related Experiment Videos

Main Results:

  • TGB demonstrated efficacy as add-on therapy for partial seizures in doses of 30-56 mg daily.
  • It exhibits linear and predictable pharmacokinetics.
  • Common adverse events include dizziness, somnolence, and asthenia, typically mild to moderate.

Conclusions:

  • Tiagabine (TGB) is an effective AED for partial seizures in medically refractory epilepsy.
  • It has a favorable pharmacokinetic profile with minimal interactions.
  • Further studies are needed to confirm monotherapy efficacy and optimal dosing.